Enanta Pharmaceuticals Inc (ENTA) USD0.01
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.